The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

• Authors: PERUSINI MA.; KIM TS.; ŽÁČKOVÁ Daniela; PAGNANO K.; MAYER Jiří; PAVLOVSKY C.; JEŽÍŠKOVÁ Ivana; KVETKOVÁ Anežka; JURČEK Tomáš; MOIRAGHI B; VARELA AI.; BIANCHINI M.; LOPES ABP.; DUARTE G.; YOO YS.; SOUZA CA.; MEDEIROS J.; LEE HW.; KIM KH.; YI SY.; CHANG MH.; ABELSON S.; KIM DDH.
• Year of publication: 2022
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine